The platelet C-type lectin-like receptor CLEC-2 drives inflammation-driven venous
thrombosis in mouse models of thrombo-inflammatory disease with a minimal effect on …

Antiplatelet therapy aims to reduce the risk of thrombotic events while maintaining
hemostasis. A promising current approach is the inhibition of platelet glycoprotein GPVI …

The platelet-activating collagen receptor GPVI represents the focus of clinical trials as an
antiplatelet target for arterial thrombosis, and soluble GPVI is a plasma biomarker for several …

Background The platelet–signaling receptor glycoprotein VI (GPVI) is a promising
antithrombotic target. We have previously raised a series of high-affinity nanobodies (Nbs) …

GPVI and CLEC-2 have emerged as promising targets for long-term prevention of both
arterial thrombosis and thrombo-inflammation with a decreased bleeding risk relative to …

Platelets play a crucial role on hemostasis and are also involved in cardiovascular diseases,
such as heart attack and stroke. Artesunate has been reported to possess multiple biological …

Understanding the pathways involved in the formation and stability of the core and shell
regions of a platelet-rich arterial thrombus may result in new ways to treat arterial …

Rac1 is a small Rho GTPase that is activated in platelets upon stimulation with various
ligands, including collagen and thrombin, which are ligands for the glycoprotein VI (GPVI) …

Glycoprotein (GP) VI plays a key role in collagen-induced platelet aggregation. Affimers are
engineered binding protein alternatives to antibodies. We screened and characterized GPVI …

The collagen/fibrin (ogen) receptor, glycoprotein VI (GPVI), is a platelet activating receptor
and a promising anti-thrombotic drug target. However, while agonist-induced GPVI …